-+ 0.00%
-+ 0.00%
-+ 0.00%

CANDEL THERAPEUTICS - AGLATIMAGENE PLUS VALACYCLOVIR WELL TOLERATED; GRADE 3 ADVERSE EVENTS IN 13.7% OF PATIENTS

路透·10/01/2026 12:06:13

請登錄查看新聞詳情